ReviewMedical oncology (Northwood, London, England)2025
Triple-negative breast cancer: challenges, advances, and promising therapeutic interventions.
Review in Medical oncology (Northwood, London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Ionomycin enhances radiosensitivity in breast cancer through reactive oxygen species generation and mitochondrial permeability transition pore opening.Medical gas research · 2026Article
- Systems-Level Multi-Omics Analysis Resolves the Mechanism of Action of a Novel Multifunctional Nanosystem Against Triple-Negative Breast Cancer.Pharmaceutics · 2026Article
- A Pyrone Glucoside fromBiomolecules · 2026Article
- The m6A reader IGF2BP3 promotes triple-negative breast cancer metastasis through HOXB9-IL15RA pathway.Functional & integrative genomics · 2026Article
- Targeted Therapies for Each Subtype of Breast Cancer.MedComm · 2026Review
- KCTD15 Enhances Stem Cell-Like Properties and Promotes Triple-Negative Breast Cancer Progression Through KLF4/β-Catenin Signaling.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026Article
- Cancer-associated adipocyte promote progression and immunosuppression in triple-negative breast cancer.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Triple-Negative breast cancer (TNBC) is the most aggressive subtype of breast cancer (BC), characterized by absence of estrogen, progesterone, and human epidermal growth factor receptor 2 (HER2). Approximately, 10-15% of BC patients are diagnosed with triple-negative breast cancer. In this review, we have summarized the approaches used for the treatment of triple-negative breast cancer. Due to the complex genetic makeup, Triple-Negative breast cancer has high potential for metastasis and is inherently difficult to treat and poses a grave threat. This review analyzes and provides insight into advancements in treatment methods and diagnostic techniques for TNBC. Schiff base compounds, capable of inducing apoptosis in malignant cells, are effective dual inhibitors of histone deacetylase type II and topoisomerase I. Detection strategies like advanced imaging techniques like core biopsy and automated breast ultrasound are important for enhancing TNBC diagnosis and treatment. The progress in developing combination therapies and improving drug delivery mechanisms has to be maintained in order to tackle the challenges in treatment. This work emphasizes the need for teamwork in the development of therapeutic approaches, which may offer new possibilities in the treatment of TNBC.
Indexed as
Identifiers
41032139What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.